Dr Chrissie Thirlwell

Job title

Senior lecturer and consultant medical oncologist

Qualifications

BSc, MBBS, PhD, FRCP

GMC Number

4412304

Contact details

Phone number: 020 7794 0500 ext 38364

Email address: christina.thirlwell@nhs.net

PA/secretary email address: cedric.michael@nhs.net

Related services

Cancer services

Biography

Dr Chrissie Thirlwell is a medical oncologist and lead physician in the neuroendocrine tumour (NET) and hepatocellular cancer (HCC) multidisciplinary clinics. She leads a research team at the UCL Cancer Institute working on integrated genomic analysis and the use of circulating biomarkers in NET management. The NET and HCC teams have an extensive clinical trial portfolio leading to tertiary and international referrals.  Dr Thirlwell has a national and international reputation for the management of and research in NETs. 

Publications

  • Somatic mutation of CDKN1B in small intestinal neuroendocrine tumors. Nature Genetics. Francis J et al. 2013 Nov 3. doi: 10.1038/ng.2821.
  • Epigenetic dysregulation and poorer outcome in DAXX deficient PNETs. C Pipinikas et al, C Thirlwell Senior Author. Endocr Relat Cancer. 2015 Jun;22(3):L13-8.
  • Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumour. Karpathakis et al, C Thirlwell Senior Author. Clin Cancer Res. 2016 Jan 1;22(1):250-8
  • Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Ann Transl Med. 2015 Jun;3(9):118.
  • Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. Neuroendocrinology. 2015;102(1-2):68-76.
  • PTH-093 Chromogranin-A : Can It Predict Radiological Progression In Neuroendocrine Tumours? Gut. 06/2014; 63(Suppl 1):A251. DOI: 10.1136/gutjnl-2014-307263.539
  • Neuroendocrine tumours: Cracking the epigenetic code. C Thirlwell Senior Author End. Rel. Cancer. 2013 May 20;20(3):R65-82.
  • Hitting the target - where do molecularly targeted therapies fit in the treatment of neuroendocrine tumours? C Thirlwell Senior Author End. Rel. Cancer. 2012 May 24;19(3):R73-92.
  • Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology. 2014 Jan 21
  • Appendiceal goblet cell tumour: a case of unexpected lung metastasis. Case Rep Oncol. 2012 May;5(2):332-8.